We are focused on the discovery and development of novel biologic therapies for the treatment of fibrosis, a process of excessive undesirable scarring which is a major unmet medical need in many different human diseases. Our initial areas of interest are fibrosis of the liver (NASH) and musculoskeletal system, including Dupuytren’s disease – a fibrotic disease of the hand.

Dupuytren’s disease

Dupuytren’s disease is a common but not well-known condition where up to 4% of the population can be afflicted. The later stages of the disease are characterized by irreversible curling of the fingers towards the palm, which can be extremely debilitating and lead to amputation in the most severe cases. There is no approved treatment for early disease or preventing recurrence, which occurs following surgery or collagenase injection for late disease.

We have recently completed a Phase 2a dosing study and based on successful results, have initiated a Phase 2b anti-fibrosis clinical efficacy trial in patients with Dupuytren’s disease, with support from the Wellcome Trust and the United Kingdom Department of Health.